Merck & Co. said on November 20 that its global phase 3 TroFuse-015 trial of investigational drug sacituzumab tirumotecan (sac-TMT) met its primary overall survival (OS) endpoint in patients with locally advanced, unresectable or metastatic gastroesophageal adenocarcinoma. Participants had previously received at least two lines of systemic therapy. The trial did not meet its secondary progression-free survival (PFS) endpoint, leaving a mixed picture of the drug’s efficacy.
Overall survival improves versus physician’s choice
In the final analysis, sac-TMT delivered a statistically significant and clinically meaningful improvement in OS compared with treatment of physician’s choice (TPC), Merck said. TPC options included trifluridine/tipiracil, irinotecan, paclitaxel or docetaxel, selected by the treating physician.
Merck said the study is the first global phase 3 trial to show an OS benefit from a TROP2-targeted antibody-drug conjugate (ADC) in this patient population. Sac-TMT is an investigational TROP2-targeted ADC licensed by Merck from Kelun-Biotech.
Results were generally consistent across patient subgroups, with no clear differences based on TROP2 expression status, the company said. Merck did not disclose the size of the OS benefit or figures such as the hazard ratio, making it difficult to assess the magnitude of the effect from the information released.
PFS endpoint missed; no new safety signals reported
The study did not meet its prespecified secondary PFS endpoint. The objective response rate (ORR) results nominally favored sac-TMT, but investigators did not formally test this secondary endpoint under the prespecified analysis plan. The ORR finding therefore has not been confirmed through formal statistical testing.
Merck said sac-TMT’s safety profile was consistent with previous studies and that no new safety signals were identified. The OS result, the missed PFS endpoint and the untested ORR observation make up the main efficacy and safety findings disclosed so far.
TroFuse program includes 18 global phase 3 trials
TroFuse-015 is the second phase 3 study in Merck’s global TroFuse development program to report a positive result. The program currently includes 18 ongoing global phase 3 trials across cancer types and stages of treatment. Merck describes it as the broadest TROP2-targeted ADC program in terms of the diseases and treatment settings covered.
The company is evaluating sac-TMT both as a single agent and in combination with immunotherapies. Trials span endometrial, bladder, breast, cervical, gastric, non-small cell lung and ovarian cancers. TroFuse-015 is one of 14 phase 3 studies in the program. For Merck’s oncology pipeline, the gastric cancer trial adds an OS-positive result, while its PFS outcome fell short of the prespecified target.